Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated Interferon α-2b + Ruxolitinib in Polycythemia Vera
NCT05870475Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jun 2023
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ruxolitinib in polycythemia vera (PV) (2 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Cumulative Complete Hematologic Response Rate at 24 weeks. Started Jun 2023; status: recruiting.
02
Drugs
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on NCT05870475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05870475.